Explore our company news, announcements and updates
October 1, 2026
Merck Animal Health Highlights Landmark Clinical Research on Gilvetmab, the First Caninized Immune Checkpoint Inhibitor for Canine Oncology in the Journal of Veterinary Internal Medicine and Journal of the American Veterinary Medical Association
Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages
In Observance of Mental Health Awareness Month, Merck Animal Health Announces Inaugural Veterinary Wellbeing Collective to Help Advance Veterinary Wellbeing
FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs
FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis
Merck Animal Health Wins 2025 S&P Global Award in Best Product and Best Product Companion Animal Food Animal Categories for NUMELVI and INNOVAX® ND-IBD-ILT, Respectively
Go To United States
Algeria
Argentina
Australia
Austria
Bahrain
Belgium (Dutch)
Brazil
Canada (English)
Chile
Colombia
Croatia
Czech Republic
Denmark
Ecuador
Egypt
Finland
France
Germany
Greece
Hungary
India
Indonesia
Iraq
Ireland
Israel
Italy
Japan
Jordan
Kuwait
Lebanon
Malaysia
Mexico
Morocco
Netherlands
New Zealand
Norway
Oman
Panama
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russian Federation
Saudi Arabia
South Africa
South Korea
Spain
Sweden
Switzerland (French)
Taiwan
Thailand
Tunisia
Turkey
Ukraine
United Arab Emirates
United Kingdom
Uruguay
Yemen